GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (STU:8CC) » Definitions » Cyclically Adjusted Price-to-FCF

Cocrystal Pharma (STU:8CC) Cyclically Adjusted Price-to-FCF : (As of May. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cocrystal Pharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cocrystal Pharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cocrystal Pharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cocrystal Pharma Cyclically Adjusted Price-to-FCF Chart

Cocrystal Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cocrystal Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cocrystal Pharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Cocrystal Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cocrystal Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Cyclically Adjusted Price-to-FCF falls into.



Cocrystal Pharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cocrystal Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Cocrystal Pharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.408/131.7762*131.7762
=-0.408

Current CPI (Mar. 2024) = 131.7762.

Cocrystal Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -2.906 100.560 -3.808
201409 -2.600 100.428 -3.412
201412 -4.185 99.070 -5.567
201503 -0.757 99.621 -1.001
201506 -1.172 100.684 -1.534
201509 -1.558 100.392 -2.045
201512 -1.505 99.792 -1.987
201603 -1.882 100.470 -2.468
201606 -2.354 101.688 -3.051
201609 -1.433 101.861 -1.854
201612 -1.096 101.863 -1.418
201703 -0.983 102.862 -1.259
201706 -0.483 103.349 -0.616
201709 -0.907 104.136 -1.148
201712 -0.654 104.011 -0.829
201803 -0.831 105.290 -1.040
201806 -0.776 106.317 -0.962
201809 -0.741 106.507 -0.917
201812 -0.699 105.998 -0.869
201903 0.697 107.251 0.856
201906 -0.347 108.070 -0.423
201909 -0.495 108.329 -0.602
201912 -0.393 108.420 -0.478
202003 -0.594 108.902 -0.719
202006 -0.476 108.767 -0.577
202009 -0.545 109.815 -0.654
202012 -0.339 109.897 -0.406
202103 -0.254 111.754 -0.300
202106 -0.302 114.631 -0.347
202109 -0.564 115.734 -0.642
202112 -0.319 117.630 -0.357
202203 -0.436 121.301 -0.474
202206 -0.433 125.017 -0.456
202209 -1.105 125.227 -1.163
202212 -0.567 125.222 -0.597
202303 -0.362 127.348 -0.375
202306 -0.510 128.729 -0.522
202309 -0.247 129.860 -0.251
202312 -0.304 129.419 -0.310
202403 -0.408 131.776 -0.408

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cocrystal Pharma  (STU:8CC) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cocrystal Pharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cocrystal Pharma (STU:8CC) Business Description

Industry
Traded in Other Exchanges
Address
19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Cocrystal Pharma (STU:8CC) Headlines

No Headlines